177Lu-HX02 / Hexin (Suzhou) Pharmaceutical Technology - LARVOL DELTA

Safety, Biodistribution, and Dosimetry of 177Lu-HX02: A First-in-Human Study in Sarcoma Patients (SNMMI 2026) - "This first-in-human study demonstrates a favorable safety profile and promising targeting characteristics of 177Lu-HX02 in sarcoma patients. The agent achieves high and sustained tumor uptake, with its biodistribution strongly correlating with 68Ga-HX01, confirming its potential as a theranostic pair. Dosimetry reveals low radiation exposure to critical organs and a whole-body effective dose superior to 177Lu-DOTATATE."

Clinical • First-in-human • P1 data • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • ANPEP

Safety, Biodistribution, and Dosimetry of 177Lu-HX02: A First-in-Human Study in Sarcoma Patients (SNMMI 2026) - "This first-in-human study demonstrates a favorable safety profile and promising targeting characteristics of 177Lu-HX02 in sarcoma patients. The agent achieves high and sustained tumor uptake, with its biodistribution strongly correlating with 68Ga-HX01, confirming its potential as a theranostic pair. Dosimetry reveals low radiation exposure to critical organs and a whole-body effective dose superior to 177Lu-DOTATATE."

Clinical • First-in-human • P1 data • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • ANPEP

Phase I clinical trial to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics and preliminary efficacy of 177Lu-HX02 injection in patients with advanced malignant solid tumors (ChiCTR) - P1 | N=24 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of

New P1 trial • Solid Tumor

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Radiation Dosimetry, Pharmacokinetics, and Preliminary Efficacy of ¹⁷⁷Lu-HX02 Injection in Patients with Advanced Malignant Solid Tumors (ChiCTR) - P1 | N=24 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.

New P1 trial • Ewing Sarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor